Get started
Work

Abstract P3-06-05: Evaluation of an in vitro derived signature of olaparib response (PARPi-7) as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 TRIAL

Year: 2015
Type: conference-abstract
DOI: 10.1158/1538-7445.sabcs14-p3-06-05
Authors: Denise M Wolf, Christina Yau, Ashish Sanil, Anneleen Daemen, Laura Heiser, Joe Gray, Lamorna Brown-Swigart, Susan Flynn, Gillian Hirst, I-SPY 2 TRIAL Investigators, Meredith Buxton, Angela DeMichele, Nola Hylton, Fraser Symmans, Doug Yee, Melissa Paoloni, Laura Esserman, Don Berry, Hope Rugo, Olufunmilayo Olopade, Laura van 't Veer
Institutions: University of California System, Berry Consultants, LLC (United States), Genentech, Oregon Health & Science University, University of Pennsylvania, The University of Texas MD Anderson Cancer Center, University of Minnesota, University of Chicago
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: closed
OpenAlex ID: W2116023091
Cites:
Cited by: 3
Related to: 10